insulin detemir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4985 169148-63-4

Description:

MoleculeDescription

Synonyms:

  • insulin detemir
  • levemir
  • insulin detemir recombinant
  • insulin detemir [rDNA origin]
  • NN304
  • NN 304
  • NN-304
A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS.
  • Molecular weight: 5916.89
  • Formula: C267H402N64O76S6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 2252.82
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
40 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 1, 2004 EMA
June 16, 2005 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 690.73 13.23 417 23711 83339 63381555
Hypoglycaemia 528.47 13.23 312 23816 59753 63405141
Diabetic ketoacidosis 384.15 13.23 177 23951 20328 63444566
Blood glucose decreased 208.34 13.23 118 24010 20834 63444060
Hyperglycaemia 185.05 13.23 142 23986 41725 63423169
Diabetes mellitus inadequate control 171.79 13.23 93 24035 15033 63449861
Lactic acidosis 162.97 13.23 127 24001 38160 63426734
Gangrene 137.38 13.23 60 24068 6063 63458831
Glycosylated haemoglobin increased 131.86 13.23 73 24055 12325 63452569
Blood glucose fluctuation 126.48 13.23 52 24076 4524 63460370
Arterial occlusive disease 110.16 13.23 51 24077 5907 63458987
Ketoacidosis 105.09 13.23 45 24083 4333 63460561
Acute kidney injury 86.88 13.23 258 23870 263157 63201737
Hypoglycaemic unconsciousness 86.28 13.23 25 24103 752 63464142
Exposure during pregnancy 84.37 13.23 184 23944 155363 63309531
Drug ineffective 83.07 13.23 171 23957 1044594 62420300
Drug intolerance 78.17 13.23 12 24116 308649 63156245
Hypoglycaemic coma 73.68 13.23 30 24098 2545 63462349
Diabetic retinopathy 69.64 13.23 28 24100 2299 63462595
Treatment failure 63.07 13.23 3 24125 199040 63265854
Angina pectoris 62.98 13.23 67 24061 30011 63434883
Injection site mass 60.75 13.23 53 24075 18603 63446291
Blood glucose abnormal 58.99 13.23 37 24091 7855 63457039
Alopecia 57.87 13.23 28 24100 337508 63127386
Premature delivery 57.38 13.23 64 24064 30217 63434677
Carotid artery thrombosis 55.05 13.23 25 24103 2769 63462125
Insulin resistance 54.12 13.23 18 24110 860 63464034
Anti-insulin antibody positive 51.06 13.23 11 24117 92 63464802
Neurologic neglect syndrome 49.39 13.23 23 24105 2698 63462196
Infusion related reaction 49.22 13.23 16 24112 245505 63219389
Cerebrovascular accident 47.76 13.23 118 24010 107906 63356988
Joint swelling 46.56 13.23 34 24094 327632 63137262
Systemic infection 45.63 13.23 26 24102 4634 63460260
Arthropathy 44.15 13.23 17 24111 234775 63230119
Pancreatitis 42.64 13.23 71 24057 48984 63415910
Infective pulmonary exacerbation of cystic fibrosis 41.34 13.23 31 24097 8786 63456108
Injection site urticaria 39.93 13.23 37 24091 14036 63450858
Visceral congestion 38.02 13.23 11 24117 329 63464565
Cataract 37.36 13.23 73 24055 56980 63407914
Hypoglycaemia neonatal 37.22 13.23 14 24114 961 63463933
Therapeutic product effect decreased 34.67 13.23 15 24113 193172 63271722
Foetal exposure during pregnancy 34.35 13.23 51 24077 31911 63432983
Hepatic enzyme increased 34.31 13.23 17 24111 202311 63262583
Hypoglycaemic seizure 34.01 13.23 11 24117 481 63464413
Pre-eclampsia 33.94 13.23 28 24100 9105 63455789
Gastric disorder 33.71 13.23 55 24073 37314 63427580
Anuria 33.70 13.23 32 24096 12519 63452375
Personality disorder 33.11 13.23 23 24105 5788 63459106
Injection site erythema 32.76 13.23 87 24041 83087 63381807
Injection site pruritus 32.34 13.23 60 24068 45056 63419838
Musculoskeletal stiffness 32.08 13.23 15 24113 184603 63280291
Discomfort 31.65 13.23 12 24116 167362 63297532
Completed suicide 30.06 13.23 9 24119 145664 63319230
Product use issue 29.87 13.23 24 24104 220496 63244398
Diabetic neuropathy 28.16 13.23 18 24110 3946 63460948
Blood ketone body 27.87 13.23 6 24122 50 63464844
Fall 27.49 13.23 248 23880 392086 63072808
Abdominal discomfort 27.48 13.23 50 24078 320835 63144059
Hemiplegia 27.40 13.23 25 24103 9298 63455596
Premature baby 26.59 13.23 36 24092 20699 63444195
Arthralgia 26.49 13.23 119 24009 569591 62895303
Motor dysfunction 26.19 13.23 26 24102 10735 63454159
Hyperkalaemia 25.86 13.23 61 24067 54142 63410752
Sensory loss 25.41 13.23 25 24103 10213 63454681
Anti-insulin antibody 24.25 13.23 5 24123 33 63464861
Rhonchi 24.23 13.23 14 24114 2562 63462332
Coordination abnormal 24.20 13.23 28 24100 13745 63451149
Vomiting 24.07 13.23 321 23807 559296 62905598
Adjustment disorder 24.00 13.23 15 24113 3163 63461731
Skin haemorrhage 23.85 13.23 24 24104 10070 63454824
Affect lability 23.62 13.23 25 24103 11126 63453768
Hypoglycaemia unawareness 23.23 13.23 6 24122 116 63464778
Pancreatitis acute 23.18 13.23 39 24089 27127 63437767
Duodenal ulcer perforation 22.96 13.23 3 24125 87206 63377688
General physical health deterioration 22.39 13.23 142 23986 201260 63263634
Gestational hypertension 22.37 13.23 13 24115 2404 63462490
Anti-insulin antibody increased 21.98 13.23 5 24123 55 63464839
Therapeutic product effect incomplete 21.97 13.23 10 24118 125046 63339848
Impaired healing 21.77 13.23 6 24122 102536 63362358
Treatment noncompliance 21.16 13.23 45 24083 37280 63427614
Lower respiratory tract infection 21.12 13.23 12 24116 132295 63332599
Blood insulin decreased 21.07 13.23 4 24124 16 63464878
Neonatal anoxia 20.63 13.23 3 24125 0 63464894
Increased insulin requirement 20.42 13.23 5 24123 77 63464817
Blood pressure increased 20.38 13.23 118 24010 161944 63302950
Anaemia 20.28 13.23 185 23943 293245 63171649
Infection 20.24 13.23 35 24093 229138 63235756
Product administration error 20.24 13.23 33 24095 22364 63442530
Chest discomfort 20.12 13.23 89 24039 109880 63355014
Pain 19.88 13.23 183 23945 740445 62724449
Upper respiratory tract irritation 19.75 13.23 6 24122 213 63464681
Palpitations 19.68 13.23 90 24038 112680 63352214
Sinus congestion 19.59 13.23 29 24099 18094 63446800
Diabetic nephropathy 19.51 13.23 10 24118 1444 63463450
Diabetes mellitus 18.64 13.23 55 24073 55755 63409139
Altered state of consciousness 18.64 13.23 34 24094 25196 63439698
Acute myocardial infarction 18.52 13.23 39 24089 32085 63432809
Extradural haematoma 17.92 13.23 10 24118 1712 63463182
Euglycaemic diabetic ketoacidosis 17.40 13.23 13 24115 3661 63461233
Injection site rash 17.39 13.23 28 24100 18781 63446113
Cardiac death 17.32 13.23 7 24121 582 63464312
Dehydration 17.30 13.23 119 24009 173235 63291659
Diabetic retinal oedema 17.30 13.23 6 24122 326 63464568
Febrile neutropenia 17.17 13.23 12 24116 118437 63346457
Multiple lentigines syndrome 17.17 13.23 5 24123 153 63464741
Irritable bowel syndrome 17.16 13.23 5 24123 82407 63382487
Asphyxia 17.05 13.23 16 24112 6165 63458729
Injection site nodule 16.91 13.23 13 24115 3822 63461072
Asthenia 16.85 13.23 221 23907 383383 63081511
Sneezing 16.68 13.23 27 24101 18191 63446703
Renal impairment 16.53 13.23 72 24056 88283 63376611
Pallor 16.35 13.23 36 24092 30532 63434362
Neutropenia 16.12 13.23 26 24102 174979 63289915
Respiratory tract congestion 15.74 13.23 26 24102 17806 63447088
Renal failure 15.66 13.23 87 24041 117565 63347329
Metabolic acidosis 15.61 13.23 45 24083 45024 63419870
Aphasia 15.58 13.23 37 24091 32963 63431931
Hemiparesis 15.49 13.23 30 24098 23252 63441642
Stomatitis 15.40 13.23 18 24110 138707 63326187
Diabetic metabolic decompensation 15.31 13.23 9 24119 1701 63463193
Abortion spontaneous 15.28 13.23 46 24082 47149 63417745
Diabetic gangrene 14.94 13.23 3 24125 17 63464877
Macular oedema 14.64 13.23 12 24116 3865 63461029
C-reactive protein increased 14.53 13.23 9 24119 94698 63370196
Urogenital haemorrhage 14.41 13.23 5 24123 272 63464622
Sinus disorder 14.38 13.23 30 24098 24523 63440371
Drug level above therapeutic 14.35 13.23 13 24115 4792 63460102
Blood cholesterol increased 14.34 13.23 9 24119 94023 63370871
Jaundice neonatal 14.29 13.23 7 24121 918 63463976
Off label use 14.29 13.23 176 23952 674286 62790608
Pancreatic carcinoma 14.24 13.23 16 24112 7612 63457282
Liver injury 13.90 13.23 3 24125 60517 63404377
Paraplegia 13.89 13.23 10 24118 2662 63462232
Cataract subcapsular 13.87 13.23 6 24122 592 63464302
Vitreous haemorrhage 13.80 13.23 9 24119 2041 63462853
Shock hypoglycaemic 13.78 13.23 4 24124 121 63464773
Chronic kidney disease 13.54 13.23 43 24085 45355 63419539
Wrong product administered 13.42 13.23 14 24114 6127 63458767
Myocardial infarction 13.38 13.23 74 24054 99819 63365075
Decreased insulin requirement 13.36 13.23 4 24124 135 63464759
Cystoid macular oedema 13.34 13.23 8 24120 1567 63463327
Adenocarcinoma pancreas 13.28 13.23 7 24121 1071 63463823

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 440.52 13.16 298 17372 54342 34884919
Blood glucose increased 314.47 13.16 264 17406 66454 34872807
Diabetic ketoacidosis 175.87 13.16 111 17559 17921 34921340
Diabetes mellitus inadequate control 157.20 13.16 93 17577 13371 34925890
Blood glucose decreased 115.51 13.16 76 17594 13161 34926100
Blood glucose fluctuation 90.08 13.16 43 17627 4001 34935260
Hypoglycaemic coma 67.11 13.16 30 17640 2401 34936860
Hypoglycaemic unconsciousness 66.39 13.16 22 17648 776 34938485
Glycosylated haemoglobin increased 66.18 13.16 51 17619 11309 34927952
Anti-insulin antibody positive 60.25 13.16 15 17655 183 34939078
Hyperglycaemia 58.25 13.16 85 17585 39395 34899866
Foetal disorder 57.81 13.16 20 17650 806 34938455
Toxicity to various agents 55.96 13.16 16 17654 200346 34738915
Premature baby 54.39 13.16 58 17612 19575 34919686
General physical health deterioration 52.38 13.16 163 17507 128106 34811155
Pancreatic carcinoma metastatic 49.91 13.16 26 17644 2914 34936347
Neutropenia neonatal 48.91 13.16 17 17653 695 34938566
Foetal exposure during pregnancy 46.31 13.16 75 17595 38026 34901235
Blood glucose abnormal 39.74 13.16 29 17641 5923 34933338
Hypoglycaemic seizure 39.30 13.16 12 17658 323 34938938
Drug abuse 38.71 13.16 3 17667 99093 34840168
Injection site pruritus 37.75 13.16 30 17640 6953 34932308
Injection site mass 36.97 13.16 29 17641 6597 34932664
Injection site erythema 33.88 13.16 41 17629 15858 34923403
Ketoacidosis 33.72 13.16 23 17647 4220 34935041
Pancreatitis chronic 32.93 13.16 18 17652 2222 34937039
Acute kidney injury 32.52 13.16 264 17406 304724 34634537
VACTERL syndrome 31.60 13.16 7 17663 49 34939212
Vomiting projectile 31.22 13.16 12 17658 654 34938607
Pancreatitis 30.08 13.16 63 17607 38828 34900433
Diabetic neuropathy 29.27 13.16 21 17649 4176 34935085
Injection site urticaria 28.68 13.16 16 17654 2056 34937205
Low birth weight baby 28.60 13.16 27 17643 7878 34931383
Toe amputation 28.31 13.16 17 17653 2507 34936754
Diabetic metabolic decompensation 28.22 13.16 15 17655 1751 34937510
Drug ineffective 26.50 13.16 130 17540 456621 34482640
Product monitoring error 26.24 13.16 20 17650 4361 34934900
Dehydration 25.93 13.16 132 17538 129837 34809424
Diabetic gangrene 25.19 13.16 8 17662 246 34939015
Product prescribing error 25.00 13.16 43 17627 22884 34916377
Pancreatic carcinoma 24.12 13.16 26 17644 8875 34930386
Completed suicide 23.65 13.16 10 17660 98158 34841103
Diabetic retinopathy 22.37 13.16 13 17657 1804 34937457
Febrile neutropenia 22.04 13.16 22 17648 136827 34802434
Laryngeal leukoplakia 20.56 13.16 5 17665 55 34939206
Hypoglycaemia unawareness 20.42 13.16 6 17664 141 34939120
Adenocarcinoma pancreas 20.08 13.16 11 17659 1363 34937898
Oedema peripheral 20.04 13.16 116 17554 119696 34819565
Exposure to communicable disease 20.03 13.16 6 17664 151 34939110
Hemivertebra 19.96 13.16 6 17664 153 34939108
Anaemia vitamin B12 deficiency 18.03 13.16 7 17663 392 34938869
Diabetic foot 17.30 13.16 13 17657 2775 34936486
Infective pulmonary exacerbation of cystic fibrosis 16.93 13.16 19 17651 6782 34932479
Device failure 16.83 13.16 12 17658 2364 34936897
Hypoglycaemia neonatal 16.78 13.16 11 17659 1890 34937371
Injection site rash 16.60 13.16 15 17655 4138 34935123
Injection site pain 16.27 13.16 50 17620 38955 34900306
Product quality issue 16.07 13.16 30 17640 17005 34922256
Insulin-requiring type 2 diabetes mellitus 15.99 13.16 5 17665 146 34939115
Diabetes mellitus 15.89 13.16 56 17614 46817 34892444
Forced expiratory volume decreased 15.70 13.16 13 17657 3190 34936071
Funguria 15.56 13.16 4 17666 56 34939205
Injection site nodule 15.50 13.16 10 17660 1673 34937588
Injection site irritation 15.32 13.16 9 17661 1274 34937987
Diabetic coma 15.25 13.16 8 17662 909 34938352
Dyspnoea 15.22 13.16 271 17399 376511 34562750
Infusion related reaction 15.22 13.16 4 17666 53053 34886208
Syncope 14.93 13.16 88 17582 91363 34847898
Shock haemorrhagic 14.68 13.16 23 17647 11331 34927930
Diabetic foot infection 14.45 13.16 7 17663 672 34938589
Lack of application site rotation 14.27 13.16 4 17666 79 34939182
Urogenital infection fungal 14.24 13.16 3 17667 16 34939245
Pneumobilia 13.95 13.16 4 17666 86 34939175
Shock hypoglycaemic 13.46 13.16 4 17666 98 34939163
Injection site ulcer 13.29 13.16 5 17665 257 34939004

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 790.66 11.92 510 33743 101084 79609051
Blood glucose increased 620.63 11.92 461 33792 114514 79595621
Diabetic ketoacidosis 463.27 11.92 246 34007 33876 79676259
Diabetes mellitus inadequate control 268.75 11.92 153 34100 24111 79686024
Blood glucose decreased 201.85 11.92 131 34122 26103 79684032
Hyperglycaemia 199.24 11.92 195 34058 70140 79639995
Blood glucose fluctuation 150.16 11.92 68 34185 6614 79703521
Lactic acidosis 135.46 11.92 159 34094 70200 79639935
Ketoacidosis 127.77 11.92 64 34189 7790 79702345
Gangrene 125.45 11.92 66 34187 8898 79701237
Acute kidney injury 119.67 11.92 490 33763 518914 79191221
Glycosylated haemoglobin increased 119.06 11.92 84 34169 19176 79690959
Hypoglycaemic unconsciousness 117.91 11.92 36 34217 1147 79708988
Hypoglycaemic coma 111.92 11.92 50 34203 4710 79705425
Anti-insulin antibody positive 96.69 11.92 23 34230 273 79709862
Drug ineffective 85.47 11.92 214 34039 1080699 78629436
Arterial occlusive disease 84.77 11.92 50 34203 8406 79701729
Diabetic retinopathy 80.70 11.92 35 34218 3071 79707064
General physical health deterioration 79.16 11.92 279 33974 274959 79435176
Blood glucose abnormal 62.80 11.92 45 34208 10521 79699614
Injection site mass 60.94 11.92 58 34195 20126 79690009
Completed suicide 55.84 11.92 18 34235 245749 79464386
Drug intolerance 55.48 11.92 22 34231 264097 79446038
Pancreatitis 51.76 11.92 100 34153 68475 79641660
Infective pulmonary exacerbation of cystic fibrosis 50.81 11.92 43 34210 12808 79697327
Infusion related reaction 50.32 11.92 18 34235 230219 79479916
Carotid artery thrombosis 50.02 11.92 25 34228 3028 79707107
Hypoglycaemic seizure 49.18 11.92 17 34236 807 79709328
Diabetic neuropathy 47.69 11.92 31 34222 6185 79703950
Treatment failure 47.58 11.92 8 34245 170478 79539657
Exposure during pregnancy 46.48 11.92 121 34132 101011 79609124
Joint swelling 46.11 11.92 34 34219 288612 79421523
Pancreatic carcinoma metastatic 45.15 11.92 25 34228 3728 79706407
Angina pectoris 43.47 11.92 79 34174 51653 79658482
Neurologic neglect syndrome 42.37 11.92 22 34231 2885 79707250
Injection site urticaria 40.91 11.92 38 34215 12788 79697347
Contraindicated product administered 40.56 11.92 9 34244 157529 79552606
Cataract 40.22 11.92 85 34168 62035 79648100
Dehydration 37.78 11.92 208 34045 247979 79462156
Injection site pruritus 37.36 11.92 66 34187 42217 79667918
Insulin resistance 37.34 11.92 16 34237 1363 79708772
Diabetic metabolic decompensation 36.84 11.92 21 34232 3311 79706824
Arthropathy 36.78 11.92 15 34238 177096 79533039
Gastric disorder 36.44 11.92 61 34192 37372 79672763
Anti-insulin antibody 35.94 11.92 8 34245 69 79710066
Pancreatitis chronic 35.72 11.92 22 34231 3997 79706138
Drug abuse 33.42 11.92 14 34239 162677 79547458
Cerebrovascular accident 32.84 11.92 143 34110 155149 79554986
Alopecia 32.33 11.92 31 34222 231324 79478811
Diabetic gangrene 32.23 11.92 9 34244 208 79709927
Febrile neutropenia 32.23 11.92 31 34222 230968 79479167
Product prescribing error 32.17 11.92 64 34189 44749 79665386
Hypoglycaemia unawareness 31.40 11.92 9 34244 229 79709906
Injection site erythema 31.36 11.92 89 34164 78108 79632027
Toxicity to various agents 31.17 11.92 86 34167 421454 79288681
Hyperkalaemia 31.14 11.92 114 34139 114284 79595851
Glossodynia 30.78 11.92 4 34249 103333 79606802
Pancreatitis acute 29.96 11.92 66 34187 49538 79660597
Pericarditis 28.84 11.92 5 34248 104231 79605904
Musculoskeletal stiffness 28.74 11.92 20 34233 174988 79535147
Adenocarcinoma pancreas 28.53 11.92 15 34238 2018 79708117
Anaemia 28.38 11.92 304 33949 444711 79265424
Personality disorder 27.29 11.92 22 34231 6124 79704011
Euglycaemic diabetic ketoacidosis 27.26 11.92 23 34230 6821 79703314
Anti-insulin antibody increased 27.26 11.92 7 34246 116 79710019
Injection site nodule 26.93 11.92 18 34235 3762 79706373
Premature delivery 26.62 11.92 41 34212 23426 79686709
Product quality issue 26.22 11.92 50 34203 33890 79676245
Blood ketone body 26.17 11.92 7 34246 137 79709998
Systemic infection 25.66 11.92 26 34227 9726 79700409
Visceral congestion 25.58 11.92 11 34242 945 79709190
Off label use 25.55 11.92 258 33995 906957 78803178
Increased insulin requirement 24.35 11.92 7 34246 180 79709955
Anuria 24.31 11.92 37 34216 20926 79689209
Anaemia vitamin B12 deficiency 24.20 11.92 10 34243 778 79709357
Toe amputation 24.03 11.92 17 34236 3894 79706241
Therapeutic product effect decreased 24.02 11.92 21 34232 163842 79546293
Arthralgia 23.82 11.92 146 34107 571657 79138478
Diabetes mellitus 23.81 11.92 81 34172 78309 79631826
Hepatic enzyme increased 23.77 11.92 26 34227 182584 79527551
Vomiting 23.53 11.92 409 33844 665419 79044716
Syncope 23.14 11.92 144 34109 179305 79530830
Affect lability 22.57 11.92 26 34227 11233 79698902
Chronic kidney disease 22.46 11.92 71 34182 66083 79644052
Lower respiratory tract infection 22.25 11.92 14 34239 129206 79580929
Product monitoring error 22.09 11.92 23 34230 8883 79701252
Vomiting projectile 21.61 11.92 12 34241 1799 79708336
Laryngeal leukoplakia 21.28 11.92 5 34248 56 79710079
Skin haemorrhage 21.27 11.92 26 34227 11955 79698180
Infection 21.25 11.92 45 34208 241667 79468468
Discomfort 21.09 11.92 14 34239 125603 79584532
Device failure 20.84 11.92 19 34234 6242 79703893
Motor dysfunction 19.98 11.92 28 34225 14705 79695430
Diabetic coma 19.78 11.92 10 34243 1241 79708894
Sensory loss 19.60 11.92 26 34227 12965 79697170
Blood cholesterol increased 19.23 11.92 6 34247 83714 79626421
Rhonchi 19.10 11.92 15 34238 4021 79706114
Pre-eclampsia 18.95 11.92 19 34234 7022 79703113
Treatment noncompliance 18.58 11.92 57 34196 52211 79657924
Gestational hypertension 18.54 11.92 11 34242 1868 79708267
Dyspnoea 18.48 11.92 490 33763 856535 78853600
Diabetic foot 18.28 11.92 14 34239 3618 79706517
Hemiplegia 18.22 11.92 27 34226 14912 79695223
Neutropenia 18.19 11.92 63 34190 287647 79422488
Fall 18.09 11.92 302 33951 487327 79222808
Visual impairment 18.08 11.92 83 34170 92048 79618087
Upper respiratory tract irritation 17.95 11.92 6 34247 257 79709878
Asthenia 17.93 11.92 314 33939 511375 79198760
Injection site irritation 17.76 11.92 14 34239 3776 79706359
Product administration error 17.70 11.92 41 34212 31805 79678330
Injection site rash 17.13 11.92 29 34224 17925 79692210
Adjustment disorder 17.09 11.92 14 34239 3986 79706149
Product use in unapproved indication 17.08 11.92 53 34200 250306 79459829
Accidental underdose 16.96 11.92 8 34245 854 79709281
Metabolic acidosis 16.68 11.92 75 34178 82454 79627681
Coordination abnormal 16.57 11.92 28 34225 17284 79692851
Insulin-requiring type 2 diabetes mellitus 16.38 11.92 5 34248 159 79709976
Diabetic nephropathy 16.26 11.92 12 34241 2935 79707200
Product dispensing error 16.22 11.92 24 34229 13239 79696896
Diabetic retinal oedema 16.12 11.92 6 34247 353 79709782
Type 1 diabetes mellitus 15.62 11.92 17 34236 6902 79703233
Chest discomfort 15.49 11.92 107 34146 137937 79572198
Therapeutic product effect incomplete 15.49 11.92 23 34230 141622 79568513
Duodenal neoplasm 15.43 11.92 4 34249 69 79710066
Multiple lentigines syndrome 15.41 11.92 5 34248 195 79709940
Insulin autoimmune syndrome 15.04 11.92 6 34247 426 79709709
Cellulitis 14.99 11.92 89 34164 108971 79601164
Sinus congestion 14.99 11.92 29 34224 19867 79690268
Nonreassuring foetal heart rate pattern 14.73 11.92 3 34250 16 79710119
Lack of application site rotation 14.51 11.92 4 34249 88 79710047
Intentional product use issue 14.50 11.92 27 34226 152085 79558050
Pancreatic carcinoma 14.40 11.92 23 34230 13554 79696581
Blood insulin decreased 14.29 11.92 3 34250 19 79710116
Urogenital infection fungal 14.29 11.92 3 34250 19 79710116
Injection site pain 14.19 11.92 100 34153 129738 79580397
Hemiparesis 14.11 11.92 39 34214 33694 79676441
Sneezing 13.99 11.92 28 34225 19655 79690480
Product use issue 13.90 11.92 45 34208 209777 79500358
Oedema peripheral 13.64 11.92 167 34086 252121 79458014
Injection site hypersensitivity 13.31 11.92 9 34244 1916 79708219
Blood pressure increased 13.26 11.92 144 34109 211216 79498919
Abdominal discomfort 13.23 11.92 59 34194 250668 79459467
Mobility decreased 13.20 11.92 20 34233 122155 79587980
Impaired healing 13.13 11.92 11 34242 87644 79622491
Dizziness 12.78 11.92 306 33947 526135 79184000
Acute myocardial infarction 12.67 11.92 66 34187 76970 79633165
Sinus disorder 12.57 11.92 29 34224 22435 79687700
Decreased insulin requirement 12.55 11.92 4 34249 147 79709988
Forced expiratory volume decreased 12.35 11.92 16 34237 7798 79702337
Device malfunction 12.34 11.92 28 34225 21420 79688715
Extradural haematoma 12.15 11.92 10 34243 2866 79707269
Injection site ulcer 12.11 11.92 6 34247 713 79709422
Exercise tolerance decreased 11.94 11.92 17 34236 9054 79701081

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AE05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
FDA CS M0011417 Insulin
FDA Chemical/Ingredient N0000004931 Insulin
FDA EPC N0000175453 Insulin Analog
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
FDA EPC N0000175944 Insulin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus indication 73211009 DOID:9351




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin receptor Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D04539 KEGG_DRUG
4017559 VANDF
4017569 VANDF
4019786 VANDF
CHEBI:5931 CHEBI
CHEMBL2104391 ChEMBL_ID
DB01307 DRUGBANK_ID
DB00030 DRUGBANK_ID
139825 RXNORM
19234 MMSL
4885 MMSL
4886 MMSL
72333 MMSL
d00262 MMSL
d04369 MMSL
d05436 MMSL
000869 NDDF
000870 NDDF
006518 NDDF
010059 NDDF
126210001 SNOMEDCT_US
414515005 SNOMEDCT_US
414518007 SNOMEDCT_US
417423002 SNOMEDCT_US
420609005 SNOMEDCT_US
96367001 SNOMEDCT_US
D000069057 MESH_DESCRIPTOR_UI
C0537270 UMLSCUI
C0795635 UMLSCUI
7735 INN_ID
16137271 PUBCHEM_CID
5186 INN_ID
118984375 PUBCHEM_CID
4FT78T86XV UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-3687 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-3687 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-3687 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-6432 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-6438 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-6438 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-6438 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1276 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1276 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1276 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1475 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1475 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1475 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-4501 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
LEVEMIR HUMAN PRESCRIPTION DRUG LABEL 1 50090-6391 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-6414 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 54868-5883 INJECTION, SOLUTION 14.20 mg SUBCUTANEOUS NDA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 68258-8977 IMPLANT 14.20 mg SOFT TISSUE NDA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 70518-1462 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections